7 Implementation

7.1

NHS trusts with responsibility for treating people with motor neurone disease (MND) should enable neurologists to consider the option of using riluzole in the way set out in section 1.

7.2

Neurologists with responsibility for patients with MND should review their current practice in line with the guidance set out in section 1.

7.3

The patient information attached to this guidance as appendix C can be drafted into local information leaflets.